Eleni Andreopoulou, M.D.
Eleni Andreopoulou, M.D.
Locations and Appointments
Please contact the doctor's office to verify that your insurance is accepted.
*Indicates this doctor is no longer accepting new patients with this insurance plan.
- HMO
- Medicare
- PPO
- EPO/POS
- CHP
- Blue Access
- Blue Connection
- EPO
- HMO
- Mediblue (Senior)
- PPO
- CBP
- Medicaid
- Medicare
- Freedom
- Liberty
- Medicare Advantage
- Metro/Core/Charter
- Community Plan
- Medicare
- HMO
- Medicare
About Eleni Andreopoulou, M.D.
"I am a medical oncologist with an expertise in breast cancer medicine. My focus is the multidisciplinary care and treatment of patients, especially those who have tumors that are high risk. Because I am a passionate advocate of personalized medicine, my goal is to develop new successful treatments that exploit our knowledge of the cancer genome and the immuno cell network for immunotherapy, in order to improve the outcomes of breast cancer patients. To do this, I actively participate in team science and recognize the importance of establishing strong connections with other disciplines involved in the care of patients and who are in the laboratory, as our goals are the same- to cure breast cancer. I view my patients as individuals and welcome open and inclusive communication when discussing treatment strategies as it is paramount they feel comfortable with an established treatment pathway."
Dr. Eleni Andreopoulou joined 91Â鶹¾«Æ· Medical Center as an Associate Professor of Clinical Medicine specializing in the care and treatment of patients with breast cancer in January 2015. Prior to this appointment she held faculty positions at the Albert Einstein College of Medicine/ Montefiore Medical Center and the University of Texas M.D. Anderson Cancer Center.
Dr. Andreopoulou completed her training in major academic institutions in both Europe and the U.S. After she completed her residency in Internal Medicine at St Bartholomew`s Hospital in London she was awarded a European Society of Medical Oncology fellowship and trained in Medical Oncology at the Royal Marsden Hospital/Institute of Cancer Research in London, UK. She received laboratory training in the signal transduction and molecular pharmacology laboratory studying correlations between drug sensitivity and constitutive gene expression gaining a unique learning experience in a model hybrid clinical/laboratory facility. Subsequently, she completed her fellowship in Hematology and Medical Oncology at the New York University School of Medicine. In addition to intensive and comprehensive clinical training this experience was key to her understanding of the complexities in preclinical and clinical evaluation of anticancer drugs and established a strong foundation in her career. In addition to her active clinical practice her strength to the 91Â鶹¾«Æ· Medical Center team is her demonstrated passion for biomarker-driven clinical trials, pharmacogenomic predictors of chemoresistance, chemosensitivity, and endocrine sensitivity for early and advanced stage breast cancer. Most importantly, she conceptualized and established a prospective bio-repository in breast cancer providing a crucial foundation for precision medicine research. She asse